<html>
<head>PUBMED IDs for IL-28R1</head>
<body bgcolor='#C5F0F2'><h1>IL-28R1</h1><a href='https://pubmed.ncbi.nlm.nih.gov/15850793/'>SOCS-1 inhibits expression of the antiviral proteins 2',5'-OAS and MxA induced by the novel interferon-lambdas IL-28A and IL-29.</a> April 27  2005<br><a href='https://pubmed.ncbi.nlm.nih.gov/19798076/'>Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines.</a> January 16  2009<br><a href='https://pubmed.ncbi.nlm.nih.gov/20103601/'>Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis.</a> November 11  2010<br><a href='https://pubmed.ncbi.nlm.nih.gov/20655797/'>IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties.</a> January 14  2010<br></body></html>
